Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05636228 · ClinicalTrials.gov registry record · Phase 2
Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis
A Phase 2 study of Acute Infectious Keratoconjunctivitis, sponsored by Invirsa.
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
- 12
- Study locations
NCT05636228 is a Phase 2 study of Acute Infectious Keratoconjunctivitis that has completed, run by Invirsa. The registered enrollment target is 93 participants. The trial reports 12 study locations across 7 states.
The verdict
NCT05636228, a Phase 2 study of Acute Infectious Keratoconjunctivitis, has completed, sponsored by Invirsa.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
- 12
- Study locations
Study Summary
Phase 2, randomized study to assess topically administered eyedrops of INV-102 compared to vehicle during 1-week dosing in participants with Acute Infectious Keratoconjunctivitis (AIK). Participants will return for a follow up visit 1 week after end of treatment.
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG INV-102
Study Locations (12)
Florida
- Shettle Eye Research - Largo
- D & H National Research Centers, INC - Miami
- My Community Research Center, Inc. - Miami
- Quantum Clinical Trials - Miami Beach
California
- Global Research Management - Glendale
- Foothill Eye Institute - Pasadena
Other
- King Chulalongkorn Memorial Hospital - Bangkok
- Mahidol university - Bangkok
Kansas
- Kannarr Eye Center - Pittsburg
North Carolina
- Oculos Clinical Research - Garner
Ohio
- Athens Eye Care - Athens
Texas
- Revolution Research/ Lake Travis Eye and Laser Center - Lakeway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2023-06-09 |
| Est. Completion | 2024-08-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05636228
The ClinicalTrials.gov registry entry for NCT05636228 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Invirsa, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Infectious Keratoconjunctivitis appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT05636228 reports 12 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Other.
Frequently Asked Questions
What is clinical trial NCT05636228 about?
NCT05636228 is a clinical study titled "Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis". Phase 2, randomized study to assess topically administered eyedrops of INV-102 compared to vehicle during 1-week dosing in participants with Acute Infectious Keratoconjunctivitis (AIK). Participants will return for a follow up visit 1 week after end of treatment.
What is the current status of trial NCT05636228?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2023-06-09. Estimated completion is 2024-08-22.
What conditions does trial NCT05636228 study?
This clinical trial studies the following conditions: Acute Infectious Keratoconjunctivitis.
What interventions are being tested in trial NCT05636228?
The interventions under investigation include: Vehicle (DRUG), INV-102 (DRUG).
Who is sponsoring clinical trial NCT05636228?
This trial is sponsored by Invirsa, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05636228 being conducted?
This trial has 12 study locations across California, Florida, Kansas, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.